Open Access
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
Article Number 03090
Number of page(s) 12
Section Environmental Sustainable Development and Industrial Transformation
Published online 09 September 2021
  1. Du Toit, A., Outbreak of a novel coronavirus. Nat Rev Microbiol, 2020. 18(3): p. 123. [Google Scholar]
  2. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395(10223): p. 497–506. [Google Scholar]
  3. Full Text: Fighting COVID-19: China in Action. 2020. [Google Scholar]
  4. COVID-19 CORONAVIRUS PANDEMIC. 2021 [cited 2021 17 May]; Available from: . [Google Scholar]
  5. Callaway, E. and D. Cyranoski, China coronavirus: Six questions scientists are asking. Nature, 2020. 577(7792): p. 605–607. [Google Scholar]
  6. Li, W., et al., Characteristics of Household Transmission of COVID-19. Clin Infect Dis, 2020. 71(8): p. 1943–1946. [Google Scholar]
  7. Coronavirus disease (COVID-19): How is it transmitted? 2021; Available from: [Google Scholar]
  8. Rothe, C., et al., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med, 2020. 382(10): p. 970–971. [Google Scholar]
  9. Symptoms of Coronavirus. [Google Scholar]
  10. Carly Eastin, T.E., Clinical Characteristics of Coronavirus Disease 2019 in China Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. The Journal of Emergency Medicine, 2020. 58(4): p. 711–712. [Google Scholar]
  11. Coronavirus. . Available from: [Google Scholar]
  12. Who is at high risk from coronavirus (clinically extremely vulnerable. 2021. [Google Scholar]
  13. Fang, L., G. Karakiulakis, and M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med, 2020. 8(4): p. e21. [Google Scholar]
  14. Hutchins, S.S., et al., Protection of racial/ethnic minority populations during an influenza pandemic. Am J Public Health, 2009. 99 Suppl 2(Suppl 2): p. S261–70. [Google Scholar]
  15. Woo, P.C., et al., Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med (Maywood), 2009. 234(10): p. 1117–27. [Google Scholar]
  16. Cheng, V.C., et al., Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev, 2007. 20(4): p. 660–94. [Google Scholar]
  17. Zaki, A.M., et al., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 2012. 367(19): p. 1814–20. [Google Scholar]
  18. Chan, J.F., et al., Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev, 2015. 28(2): p. 465–522. [Google Scholar]
  19. He, F., Y. Deng, and W. Li, Coronavirus disease 2019: What we know? J Med Virol, 2020. 92(7): p. 719–725. [Google Scholar]
  20. Lu, R., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020. 395(10224): p. 565–574. [Google Scholar]
  21. Covid19. Available from: [Google Scholar]
  22. Wei, P.-F., Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chinese Medical Journal, 2020. 133(9): p. 1087–1095. [Google Scholar]
  23. Yang, L.M., et al., Cloning and characterization of a novel feline IFN-omega. J Interferon Cytokine Res, 2007. 27(2): p. 119–27. [Google Scholar]
  24. Lopinavir. Available from: [Google Scholar]
  25. Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med, 2020. 383(19): p. 1813–1826. [Google Scholar]
  26. Sheahan, T.P., et al., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 2020. 11(1): p. 222. [Google Scholar]
  27. Ji, S., et al., Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed Pharmacother, 2020. 121: p. 109652. [Google Scholar]
  28. COVID-19 Vaccines. 2021; Available from: [Google Scholar]
  29. Thanh Le, T., et al., The COVID-19 vaccine development landscape. Nat Rev Drug Discov, 2020. 19(5): p. 305–306. [Google Scholar]
  30. Jonathan Corum, C.Z., How the Sinovac Vaccine Works. The New York Times, 2021. [Google Scholar]
  31. Park, K.S., et al., Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev, 2021. 169: p. 137–151. [Google Scholar]
  32. Wu, Z., et al., Time Course of a Second Outbreak of COVID-19 in Beijing, China, June-July 2020. JAMA, 2020. 324(14): p. 1458–1459. [Google Scholar]
  33. Zhang, Y., et al., [Epidemiological characteristics of COVID-19 cases in outbreak in Xinfadi market in Beijing]. Zhonghua Liu Xing Bing Xue Za Zhi, 2021. 42(3): p. 1–5. [Google Scholar]
  34. Wang, X.Y., Y.Q. Zhang, and L.W. Cai, Spatiotemporal characteristics of the COVID-19 resurgence in the metropolitan wholesale market of Beijing, China. J Travel Med, 2021. 28(2). [Google Scholar]
  35. <Epidemiological investigation of COVID-19 outbreak in Dalian, Liaoning Province from July to August, 2020 .pdf>. [Google Scholar]
  36. Tegan K. Boehmer, PhD; Jourdan DeVies, MS; Elise Caruso, MPH; Katharina L. van Santen, MSPH; Shichao Tang, PhD; Carla L. Black, PhD; Kathleen P. Hartnett, PhD; Aaron Kite-Powell, MS; Stephanie Dietz, PhD; Matthew Lozier, PhD; Adi V. Gundlapalli, MD, PhD Changing Age Distribution of the COVID-19 Pandemic — United States MMWR Morb Mortal Wkly, vol, no, pp, (2020). [Google Scholar]
  37. Covid Data Tracker Weekly Review Center of Disease Control and Prevention (2021) [Google Scholar]
  38. Covid Data Tracker Weekly Review Center of Disease Control and Prevention (2021). [Google Scholar]
  39. Hannah Ritchie, Esteban Ortiz-Ospina, Diana Beltekian, Edouard Mathieu, Joe Hasell, Bobbie Macdonald, Charlie Giattino, Cameron Appel, Max Roser Statistics and Research Coronavirus (COVID-19) Vaccinations Our World In Data, vol, no, pp, (2021). [Google Scholar]
  40. Jennifer L. Kriss, PhD1; Laura E. Reynolds, MPH1; Alice Wang, PhD1; Shannon Stokley, DrPH1; Matthew M. Cole, MPH1; LaTreace Q. Harris, MPH1; Lauren K. Shaw, MS1; Carla L. Black, PhD1; James A. Singleton, PhD1; David L. Fitter, MD1; Dale A. Rose, PhD1; Matthew D. Ritchey, DPT1; Robin L. Toblin, PhD1 COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons International Committee of Medical Journal, vol 70, no 11, pp 389–395 (2021). e2.htm [Google Scholar]
  41. Ben Hu, Hua Guo, Peng Zhou & Zheng-Li Shi Characteristics of SARS-CoV-2 and COVID-19 Nature Reviews Microbiology, vol 19, no, pp 141–154(2020). [Google Scholar]
  42. Julianne Gee1; Paige Marquez1; John Su1; Geoffrey M. Calvert1; Ruiling Liu1; Tanya Myers1; Narayan Nair2; Stacey Martin1; Thomas Clark1; Lauri Markowitz1; Nicole Lindsey1; Bicheng Zhang1; Charles Licata1; Amelia Jazwa1; Mark Sotir1; Tom Shimabukuro1 First Month of COVID-19 Vaccine Safety Monitoring — United States International Committee of Medical Journal, vol 70, no 8, pp 283–288 (2020). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.